Trial Profile
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SEAVUE
- Sponsors Janssen; Janssen-Cilag
- 08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
- 17 Oct 2023 Results assessing key inflammatory mediators in CD associated with the MoA of UST and ADA in the context of a head-to-head comparator study , presented at the 31st United European Gastroenterology Week
- 27 Oct 2021 Results assessing the assess the effects of ustekinumab and adalimumab on health-related quality of life in biologic-naive patients with Crohn's Disease, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.